| Identification | Back Directory | [Name]
Lith-O-Asp | [CAS]
881179-02-8 | [Synonyms]
Lith-O-Asp
Cholan-24-oic acid, 3-[(2S)-2-amino-3-carboxy-1-oxopropoxy]-, (3α,5β)- | [Molecular Formula]
C28H45NO6 | [MDL Number]
MFCD31692386 | [MOL File]
881179-02-8.mol | [Molecular Weight]
491.66 |
| Chemical Properties | Back Directory | [Melting point ]
208-209 °C | [Boiling point ]
635.0±45.0 °C(Predicted) | [density ]
1.19±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 106 mg/mL (215.60 mM) | [form ]
Solid | [pka]
3.43±0.19(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Lith-O-Asp is a sialytransferase (ST) inhibitor, with IC50s of 12-37 μM. | [in vivo]
A significant amount of secondary metastatic cancer cells are observed in lung tissues of DMSO control mice detected using IVIS in vivo imaging system after 26 days of fat pad inoculation. However, Lith-O-Asp–treated mice show fewer lung metastases. All DMSO-treated mice confirm secondary lung metastasis, but only 3 of 8 Lith-O-Asp-treated mice show lung metastasis. Average tumor nodules per mouse are 11±9 nodules in DMSO-treated group, and 2±4 nodules in Lith-O-Asp-treated group. Additionally, significantly stronger 4T1-Luc illumination signals are shown in control mice than in those injected with Lith-O-Asp-treated cancer cells on days 7 and 9[1]. | [References]
[1] Chen JY, et al. A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res. 2011 Jan 15;71(2):473-83. DOI:10.1158/0008-5472.CAN-10-1303 |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|